Martin J Lan1, Binod Thapa Chhetry2, Conor Liston3, J John Mann2, Marc Dubin3. 1. Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA; Division of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, New York, USA. Electronic address: mjl2159@cumc.columbia.edu. 2. Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA; Division of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, New York, USA. 3. Department of Psychiatry, Weill Cornell Medical College, USA; Fell Family Brain and Mind Research Institute, Weill Cornell Medical College, USA.
Abstract
BACKGROUND: Repetitive transcranial magnetic stimulation (TMS) is an FDA-approved antidepressant treatment but little is known of its mechanism of action. Specifically, downstream effects of TMS remain to be elucidated. OBJECTIVE/HYPOTHESIS: This study aims to identify brain structural changes from TMS treatment of a treatment resistant depressive episode through an exploratory analysis. METHODS: Twenty-seven subjects in a DSM-IV current major depressive episode and on a stable medication regimen had a 3T magnetic resonance T1 structural scan before and after five weeks of standard TMS treatment to the left dorsolateral prefrontal cortex. Twenty-seven healthy volunteer (HVs) subjects had the same brain MRI acquisition. Voxel-based morphometry was performed using high dimensional non-linear diffusomorphic anatomical registration (DARTEL). RESULTS: Six clusters of gray matter volume (GMV) that were lower in pre-treatment MRIs of depressed subjects than in HVs. GMV in four of these regions increased in MDD after TMS treatment by 3.5-11.2%. The four brain regions that changed with treatment were centered in the left anterior cingulate cortex, the left insula, the left superior temporal gyrus and the right angular gyrus. Increases in the anterior cingulate GMV with TMS correlated with improvement in depression severity. CONCLUSIONS: To our knowledge, this is the first study of brain structural changes during TMS treatment of depression. The affected brain areas are involved in cognitive appraisal, decision-making and subjective experience of emotion. These effects may have potential relevance for the antidepressant action of TMS.
BACKGROUND: Repetitive transcranial magnetic stimulation (TMS) is an FDA-approved antidepressant treatment but little is known of its mechanism of action. Specifically, downstream effects of TMS remain to be elucidated. OBJECTIVE/HYPOTHESIS: This study aims to identify brain structural changes from TMS treatment of a treatment resistant depressive episode through an exploratory analysis. METHODS: Twenty-seven subjects in a DSM-IV current major depressive episode and on a stable medication regimen had a 3T magnetic resonance T1 structural scan before and after five weeks of standard TMS treatment to the left dorsolateral prefrontal cortex. Twenty-seven healthy volunteer (HVs) subjects had the same brain MRI acquisition. Voxel-based morphometry was performed using high dimensional non-linear diffusomorphic anatomical registration (DARTEL). RESULTS: Six clusters of gray matter volume (GMV) that were lower in pre-treatment MRIs of depressed subjects than in HVs. GMV in four of these regions increased in MDD after TMS treatment by 3.5-11.2%. The four brain regions that changed with treatment were centered in the left anterior cingulate cortex, the left insula, the left superior temporal gyrus and the right angular gyrus. Increases in the anterior cingulate GMV with TMS correlated with improvement in depression severity. CONCLUSIONS: To our knowledge, this is the first study of brain structural changes during TMS treatment of depression. The affected brain areas are involved in cognitive appraisal, decision-making and subjective experience of emotion. These effects may have potential relevance for the antidepressant action of TMS.
Authors: Michael D Fox; Randy L Buckner; Matthew P White; Michael D Greicius; Alvaro Pascual-Leone Journal: Biol Psychiatry Date: 2012-06-01 Impact factor: 13.382
Authors: Conor Liston; Ashley C Chen; Benjamin D Zebley; Andrew T Drysdale; Rebecca Gordon; Bruce Leuchter; Henning U Voss; B J Casey; Amit Etkin; Marc J Dubin Journal: Biol Psychiatry Date: 2014-02-05 Impact factor: 13.382
Authors: Richard Morriss; Lucy Webster; Mohamed Abdelghani; Dorothee P Auer; Shaun Barber; Peter Bates; Andrew Blamire; Paul M Briley; Cassandra Brookes; Sarina Iwabuchi; Marilyn James; Catherine Kaylor-Hughes; Sudheer Lankappa; Peter Liddle; Hamish McAllister-Williams; Alex O'Neill-Kerr; Stefan Pszczolkowski Parraguez; Ana Suazo Di Paola; Louise Thomson; Yvette Walters Journal: BMJ Open Date: 2020-07-07 Impact factor: 2.692
Authors: Timm B Poeppl; Berthold Langguth; Astrid Lehner; Thomas Frodl; Rainer Rupprecht; Peter M Kreuzer; Michael Landgrebe; Martin Schecklmann Journal: Hum Brain Mapp Date: 2017-10-24 Impact factor: 5.038
Authors: Michael Avissar; Fon Powell; Irena Ilieva; Matteo Respino; Faith M Gunning; Conor Liston; Marc J Dubin Journal: Brain Stimul Date: 2017-07-13 Impact factor: 8.955
Authors: Julius Kricheldorff; Katharina Göke; Maximilian Kiebs; Florian H Kasten; Christoph S Herrmann; Karsten Witt; Rene Hurlemann Journal: Brain Sci Date: 2022-07-15
Authors: Aaron D Boes; Brandt D Uitermarkt; Fatimah M Albazron; Martin J Lan; Conor Liston; Alvaro Pascual-Leone; Marc J Dubin; Michael D Fox Journal: Brain Stimul Date: 2018-01-31 Impact factor: 8.955
Authors: Paulo J C Suen; Sarah Doll; Marcelo C Batistuzzo; Geraldo Busatto; Lais B Razza; Frank Padberg; Eva Mezger; Lucia Bulubas; Daniel Keeser; Zhi-De Deng; Andre R Brunoni Journal: Eur Arch Psychiatry Clin Neurosci Date: 2020-04-11 Impact factor: 5.270